Back to Journals » Lung Cancer: Targets and Therapy » Volume 3

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis

Total article views   HTML views PDF downloads Totals
9,597 Dovepress* 9,250+ 1,864 11,114
PubMed Central* 347 104 451
Totals 9,597 1,968 11,565
*Since 16 July 2012
+Since July 2016

View citations on PubMed Central and Google Scholar